Silexion Therapeutics Corp (SLXN)
About Silexion Therapeutics Corp
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$11.9M
- Total assets
- $7.2M
- Market cap
- $2.0M
- Operating margin
- -44896.4%
- Net margin
- -58996.4%
Source: SEC EDGAR · updated Jun 8, 2026
Financial statements
Income statement
- Revenue
- $28.0K
- Operating expenses
- $12.6M
- Operating income
- -$12.6M
- Income tax
- $10.0K
- Net income
- -$16.5M
- EPS (basic)
- $26.36
- EPS (diluted)
- $26.36
Balance sheet
- Total assets
- $2.9M
- Current assets
- $2.2M
- Total liabilities
- $6.9M
- Current liabilities
- $3.5M
- Shareholders’ equity
- -$4.0M
Cash flow
- Operating cash flow
- -$8.4M
- Investing cash flow
- -$22.0K
- Financing cash flow
- $5.1M
- Net cash flow
- -$3.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $2.0M
- P/E ratio
- 0.1
- EPS (diluted)
- $26.36
- Shares outstanding
- 862.0K
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 16, 2024
Silexion Therapeutics Corp (SLXN) Stock Price
- Reported a net loss of $11.9M.
- Trading 98% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 0.1.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Silexion Therapeutics Corp.
Write a review
News about Silexion Therapeutics Corp
News & sentiment via Polygon.io
Silexion Therapeutics Corp: frequently asked questions
Is Silexion Therapeutics Corp an American company?
Silexion Therapeutics Corp is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Silexion Therapeutics Corp publicly traded?
Yes — Silexion Therapeutics Corp is a publicly traded company. Its stock trades under the ticker symbol SLXN on the NASDAQ.
What does Silexion Therapeutics Corp do?
Silexion Therapeutics Corp is an American Pharmaceuticals company in the Health & Beauty sector.
